{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:02:16Z","timestamp":1780048936447,"version":"3.53.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Abrocitinib, a selective Janus kinase 1 (JAK1) inhibitor, has demonstrated efficacy in moderate-to-severe atopic dermatitis (AD), although data in patients whose AD is resistant to multiple systemic therapies remain limited. We report the case of six patients with moderate-to-severe AD who were unresponsive to previous treatments, including dupilumab, tralokinumab, lebrikizumab, upadacitinib and\/or baricitinib. All patients received abrocitinib 200\u2005mg daily. After only 16 weeks, five patients achieved a good clinical response, defined as an Eczema Area Severity Index score of \u22647 and a reduction of \u22653 points in the itch Numerical Rating Scale; in three patients, this response was maintained through 32 weeks. Two patients discontinued abrocitinib due to primary or secondary inefficacy. No serious adverse events were reported; only one patient experienced mild increases in cholesterol and triglyceride levels. These findings suggest that patients with difficult-to-treat AD may benefit from therapy with abrocitinib, potentially due to its high selectivity for JAK1, which may explain its efficacy where other JAK inhibitors have failed.<\/jats:p>","DOI":"10.1093\/skinhd\/vzag045","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:38:33Z","timestamp":1771591113000},"page":"335-338","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of abrocitinib in patients with atopic dermatitis resistant to Janus kinase inhibitors"],"prefix":"10.1093","volume":"6","author":[{"given":"Elena","family":"Ippoliti","sequence":"first","affiliation":[{"name":"Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Gori","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Coscarella","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaminia","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Cannizzaro","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore , Rome ,","place":["Italy"]},{"name":"Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"2026052905173010600_vzag045-B1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic dermatitis","volume":"405","author":"Guttman-Yassky","year":"2025","journal-title":"Lancet"},{"key":"2026052905173010600_vzag045-B2","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/all.16009","article-title":"Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs","volume":"79","author":"M\u00fcller","year":"2024","journal-title":"Allergy"},{"key":"2026052905173010600_vzag045-B3","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/biomedicines12081841","article-title":"Biologic and small molecule therapy in atopic dermatitis","volume":"12","author":"Shergill","year":"2024","journal-title":"Biomedicines"},{"key":"2026052905173010600_vzag045-B4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"2026052905173010600_vzag045-B5","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/jdv.20229","article-title":"Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis","volume":"38","author":"Silverberg","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026052905173010600_vzag045-B6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s13555-024-01320-y","article-title":"Switching from dupilumab to abrocitinib in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of efficacy after treatment with dupilumab in JADE DARE","volume":"15","author":"Silverberg","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026052905173010600_vzag045-B7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2023.05.077","article-title":"An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab","volume":"89","author":"Tong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026052905173010600_vzag045-B8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/bjd\/ljad393","article-title":"Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis","volume":"190","author":"Drucker","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026052905173010600_vzag045-B9","doi-asserted-by":"crossref","first-page":"2020-8-5","DOI":"10.7573\/dic.2020-8-5","article-title":"Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib","volume":"9","author":"Nezamololama","year":"2020","journal-title":"Drugs Context"},{"key":"2026052905173010600_vzag045-B10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/3\/335\/67725171\/vzag045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/3\/335\/67725171\/vzag045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:17:37Z","timestamp":1780046257000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/3\/335\/8572460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4,2]]},"published-print":{"date-parts":[[2026,5,29]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag045","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,2]]}}}